Heart valve disease
Conditions
Interventions
an insulin group:Patients will be intravenous insulin infusion from the induction of anesthesia to discontinuation of CPB. The dosage will be regulated according to blood glucose concentration during
a control group:Patients' blood glucose will be determined every 20 minutes during surgery, and not receive insulin during surgery unless their blood glucose levels exceeded 200 mg/dl. If glucose conc
Sponsors
Dept. of Cardiovascular Surgery of Zhongshan Hospital of Fudan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria included double valve replacement, New York Heart Association (NYHA) class I-III, left ventricular ejection fraction (LVEF)>35%, normal liver and kidney function without history of liver or kidney disease, no inflammatory or immunological diseases and age>18 years.
Exclusion criteria
Exclusion criteria: Persistent smoking or smoking cessation less than 2 weeks before surgery; any concomitant diseases including acute or chronic pulmonary disease, coronary heart disease, cardiomyopathy, diabetes mellitus, thyroid disease, infective endocarditis, malignant tumor, and thoracic or spinal deformity; second cardiac operation; unstable preoperative hemodynamics; impairment of blood glucose control; and postoperative low cardiac output.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood glucose level;Plasma insulin level;Oxygen index;Inflammatory cytokines ICAM-1, TNF-a; | — |
Countries
China
Contacts
Public ContactDing Wenjun
Dept. of Thoracic Cardiovascular Surgery of Tongji Hospital of Tongji University, Shanghai
Outcome results
None listed